Screening assays using target-based affinity selection coupled with high-sensitivity detection technologies to identify smallmolecule hits from chemical libraries can provide a useful discovery approach that complements traditional assay systems. Affinity selection-mass spectrometry (AS-MS) is one such methodology that holds promise for providing selective and sensitive high-throughput screening platforms. Although AS-MS screening platforms have been used to discover smallmolecule ligands of proteins from many target families, they have not yet been used routinely to screen integral membrane proteins. The authors present a proof-of-concept study using size exclusion chromatography coupled to AS-MS to perform a primary screen for small-molecule ligands of the purified muscarinic M 2 acetylcholine receptor, a G-protein-coupled receptor. AS-MS is used to characterize the binding mechanisms of 2 newly discovered ligands. NGD-3350 is a novel M 2 -specific orthosteric antagonist of M 2 function. NGD-3366 is an allosteric ligand with binding properties similar to the allosteric antagonist W-84, which decreases the dissociation rate of N-methyl-scopolamine from the M 2 receptor. Binding properties of the ligands discerned from AS-MS assays agree with those from in vitro biochemical assays. The authors conclude that when used with appropriate small-molecule libraries, AS-MS may provide a useful high-throughput assay system for the discovery and characterization of all classes of integral membrane protein ligands, including allosteric modulators. (Journal of Biomolecular
INTRODUCTION
G -PROTEIN-COUPLED RECEPTORS (GPCRs) present many challenges to practitioners of modern drug discovery due to their structural and functional complexities. 1, 2 Most drugs presently on the market impart their agonistic or antagonistic actions by binding to the orthosteric site of GPCRs, this being the interaction site where physiologic ligands directly bind. 3 Although this binding mode can provide good drug efficacy, it can also result in problems associated with reduced receptor subtype selectivity, nonphysiologic magnitudes of receptor signaling, and inappropriate tissue selectivity. 4 Recent reports have suggested that smallmolecule allosteric modulators of GPCRs that bind outside of the orthosteric binding site, thereby leaving the orthosteric site intact for binding physiologic ligand, can have greater receptor subtype selectivity and may have greater therapeutic potential compared to orthosteric ligands. 5, 6 Thus, there is much interest in new technologies applicable to the discovery of allosteric modulators of GPCRs.
Advancements in cell-based reporter and screening methodologies now allow the discovery of all classes of GPCR ligands, including allosteric modulators. Because they are considered to be more physiologically relevant, cell-based functional assays are currently the preferred format for most primary high-throughput screening (HTS) campaigns. 6, 7 Although non-cell-based biochemical assays remain essential for studying the biophysical nature of receptor-ligand interactions, these assays are less commonly used in primary HTS campaigns in GPCR drug discovery. This is in part because of inherent limitations associated with formatting biochemical assays for high-throughput platforms. Two typical obstacles are obtaining sufficient quantities of a suitable membrane preparation, purified receptor, or signaling component (G-proteins) or a fluorescently or isotopically labeled probe. Furthermore, these screens are usually based on equilibrium binding and displacement of detectable probes that bind to the orthosteric site of the target receptor, and therefore they are inherently biased toward detection of orthosteric hits. 5, 7 Based on the allosteric ternary complex model, 8, 9 it is known that efficacious ligands that bind to nonorthosteric sites on a receptor can show negligible activities in standard equilibrium-based displacement assays. Therefore, depending on how primary screens are formatted, allosteric hits can be overlooked unless carefully sought for, or thorough follow-up assays are performed. 5, 8, 9 Screening technologies based on affinity selection from smallmolecule libraries, particularly affinity selection-mass spectrometry (AS-MS) techniques, hold promise for overcoming some of the above limitations of non-cell-based biochemical assays. [10] [11] [12] [13] When appropriately formatted, these assays are highly selective and sensitive and can provide a way of discovering many classes of smallmolecule ligands (agonist, antagonist, orthosteric, and allosteric) in a single screening campaign. Primary hits are usually identified and validated solely based on reproducible binding to the target protein and not on a secondary event, such as enzymatic activity or competitive displacement of a reporter. Although AS-MS screening technologies have been successfully used to discover and characterize small-molecule ligands to proteins of various drug target classes, [10] [11] [12] [13] [14] [15] these techniques have not yet been routinely applied to screening of integral membrane proteins.
One strategy for AS-MS-based screening involves combining a purified protein target with a library of potential ligands, thus allowing any protein-ligand complexes to form, then separating the target and bound ligands away from nonbound ligands by a rapid (< 15 sec) size exclusion chromatography (SEC) step. 14 After this separation step, the protein target and any bound ligands are immediately transferred to a reverse-phase chromatography (RPC) column, where the protein is denatured, causing bound ligands to dissociate, which are then eluted into a high-resolution mass spectrometer for detection. This particular implementation of AS-MS bears the advantages of having all reaction components in solution, so no immobilization of the protein target or small-molecule library is necessary. No radiochemical or fluorescent tags are required, and any buffers and salts, metal ions, cofactors, or detergents necessary for proper protein folding and stability may be included. Also, as is the case with most pure affinity selection-based screening methods that are not dependent on a reporter ligand displacement assay, this form of AS-MS enables the potential discovery of ligands that interact with all binding surfaces of the target protein.
In 1 AS-MS-based screening campaign, one may discover a variety of ligands having unique activities and binding modes. 14 In addition to its application as a screening tool, AS-MS has also been applied as a non-radiation-based analytical tool for characterizing the biophysical properties of receptor-ligand interactions. 16 For example, quantitative AS-MS can be used to estimate the equilibrium binding affinity of a ligand for a target. Because AS-MS permits the detection of multiple ligands bound to a target protein in a single mixture, it can also be used to analyze competi-tive equilibrium binding between differing ligands, allowing both relative affinity ranking of ligands and classification of binding mode as directly competitive or noncompetitive. 16 Ligands that are noncompetitive with orthosteric-site binding ligands have the potential of being allosteric modulators. Therefore, assay methods based on AS-MS may provide both screening and analytical technology platforms, enabling routine discovery and direct biophysical characterization of leads having orthosteric as well as allosteric binding modes.
In this report, the application of AS-MS to 3 phases of GPCR drug discovery research using the muscarinic M 2 acetylcholine receptor (AChR) as a model system is demonstrated. First, we apply AS-MS to validate the structural integrity of the orthosteric pocket of detergent-solubilized purified GPCRs that will subsequently be used for small-molecule screening. Second, AS-MS is used as an assay platform to screen a diverse combinatorial small-molecule library. We present the discovery of 2 novel ligands that bind to the purified receptor, the antagonist NGD-3350 and the allosteric ligand NGD-3366. Finally, the binding modes of new ligands to the receptor are characterized using AS-MS, and results are compared to those obtained using in vitro biological and biochemical assays. Our findings suggest that assays based on AS-MS may be routinely applicable to the discovery and characterization of multiple classes of ligands of purified GPCR targets.
EXPERIMENTAL PROCEDURES

Materials
Atropine and digitonin were purchased from Calbiochem (San Diego, CA). Scopolamine hydrobromide trihydrate (> 98% purity), N-methyl-scopolamine (NMS), R(-)-quinuclidinyl benzilate methiodide (QNB), McN-A-343, 3-isobutyl-1-methylxanthine (IBMX), FLAG-M1 antibody-agarose, and FLAG-M2 antibody were purchased from Sigma-Aldrich (St. Louis, MO). [ 2 H] 3 -Iodomethane (99.5% atom-2 H) was purchased from Cambridge Isotope Labs (Andover, MA). Forskolin, W-84 dibromide, pirenzepine dihydrochloride, arecaidine but-2-ynyl ester tosylate (ABuTs), oxotremorine-M, AF-DX-116, and AF-DX-384 were purchased from Tocris (Ellisville, MO). EDTA-free protease inhibitor tablets used for protein purification were purchased from Roche Applied Science (Indianapolis, IN). Purified bovine cyclooxygenase-1 (COX-1) was purchased from Cayman Chemical (Ann Arbor, MI). Human M 1 , M 3 , M 4 , and M 5 expressing membrane preparations were purchased from Perkin Elmer Life and Analytical Sciences (Boston, MA). Human 
Affinity purification of porcine M 2 AChR
The porcine M 2 AChR (pM 2 ) cDNA (Genbank Accession NM_214261), engineered with a honeybee melittin signal se-
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quence and FLAG-M1 epitope tag positioned upstream of the starting methionine and inserted in insect expression plasmid pVL1392, was kindly provided by Dr. E. G. Peralta. Baculovirus production and Sf9 insect cell infections were performed following standard protocols as outlined by manufacturers (BD Biosciences, San Diego, CA; Orbigen, Inc., San Diego, CA). Membrane preparations made from infected Sf9 cells typically yielded 10 to 20 pmol/mg of active receptor as determined by standard radioligand binding assays with [ 3 H]-N-methylscopolamine ([ 3 H]-NMS). Membrane preparations adjusted to 2 mg/mL were solubilized at 4°C in TBS-A (50 mM TRIS-Cl, pH 7.5, 150 mM NaCl) supplemented with 1% digitonin and protease inhibitors. The lysate was clarified by centrifugation at 100,000g for 30 min followed by 0.65 micron filtration and was diluted 5-fold in TRISbuffered saline (TBS), supplemented with 5 mM CaCl 2 , and then passed at < 0.5 mL/min through FLAG-M1 antibody-agarose resin by fast protein liquid chromatography (FPLC) overnight at 4°C. The resin was extensively washed with TBS-A and supplemented with 0.05% digitonin and 2 mM CaCl 2 , and pM 2 was eluted with 2 column volumes of TBS-A containing 5 mM EDTA, 0.1 mg/mL FLAG peptide, and 0.05% digitonin. Fractions containing pM 2 , as identified by Western blotting with an anti-FLAG-M2 antibody or specific [ 3 H]-NMS binding, were pooled and directly concentrated to greater than 20 µM by centrifugal filtration and aliquotted and stored at -80°C. The concentration of active pM 2 in a preparation was estimated, taking into account purity and AS-MS-based saturation binding data using NMS as the ligand (see Fig. 2B ). Active pM 2 concentrations used in AS-MS experiments are detailed in the figure legends.
AS-MS screening and mode-of-binding characterization
Details of the AS-MS screening method, mass encoding, and combinatorial chemical libraries used in this study have been described in detail elsewhere. 14, 16, 17 To summarize, the screening process involves combining a soluble protein (1-10 µM) and a mass-encoded small-molecule library (approximately 1500 compounds, each at 1 µM) in a suitable buffer, leading to the formation of protein-ligand complexes that are then separated from nonbinding library members by a rapid, low-temperature (< 15 sec at 4°C) SEC step. This fast separation ensures that relatively weakly bound ligands (K d < 10 µM) with moderate dissociate rates (k off < 0.1 sec -1 ) are captured. Using an integrated high-performance liquid chromatography (HPLC) system, the protein-ligand complex is then immediately transferred to an RPC column maintained at 60°C and pH < 2 to promote dissociation of the ligands. The ligands are subsequently eluted into a Waters Q-TOF highresolution quadrupole time-of-flight mass spectrometer (Manchester, UK), and tandem (MS/MS) mass spectral data are analyzed by automated software algorithms that ultimately identify bound ligand structures based on their unique molecular weights using the mass-encoding data that were associated with the input libraries used for screening. For the pM 2 screen, the affinity selec-tion step consisted of mixing 1 µL of purified protein (2 µM active pM 2 ) with 1 µL of mass-encoded library mixture at 5 mM total library concentration, followed by incubation at 25°C for 30 min before cooling to 4°C, and autosampler injection to the SEC for protein separation from the library pool, ligand dissociation from the complex, and detection by MS as described above. The affinity selection formulation consisted of detergent-solubilized pM 2 at 1 µM final active concentration in 50 mM TRIS-Cl (pH 7.5), 150 mM NaCl, 0.05% digitonin, and 2.5% DMSO, and each compound library used for affinity screening consisted of a 2500-member mixture at 2.5 mM total compound concentration (approximately 1 µM per compound). As a positive control, the detection of atropine by the AS-MS platform was used throughout the screen.
The method of dissociation constant (K d ) determinations from saturation binding and the method of affinity competition experiment (ACE 50 ) ranking of ligand affinities and characterization of the mode of binding using the same AS-MS system have been described in detail elsewhere. 16 Briefly, these experiments are based on equilibrium affinity selection, whereby a constant concentration of test ligands and serially increasing concentrations of a known competitor ligand (titrant) are incubated together with the target protein and then analyzed by AS-MS. The ability of the titrant to displace the target-bound ligands reveals the binding site classification (competitive vs. noncompetitive) and relative binding affinity ranking of these ligands. This is because the resulting MS signals of the ligands and the competitor from such experiments reflect the equilibrium concentrations of each protein-ligand complex, thereby yielding information about the equilibrium dissociation constant (K d ) of each reaction component and allowing affinity ranking. A plot of the ratio of the MS responses for the titrant and ligand will yield a straight line for directly competitive ligands or yield a hyperbolic curve for mixed-competitive or noncompetitive ligand-ligand interactions. 16 3 -NMS) was synthesized according to the literature method 18 for the parent compound with [ 2 H] 3 -iodomethane substituted for bromomethane. Briefly, 0.94 g (2.15 mmol) scopolamine hydrobromide trihydrate was dissolved in 2.5 mL water and made alkaline by combining with 0.4 g (10 mmol) sodium hydroxide in 1.5 mL water, and the free base was extracted with diethyl ether. The aqueous layer was saturated with sodium chloride and again extracted with ether, the combined extracts were dried over magnesium sulfate and filtered, and the ether was removed by rotary evaporation to yield a colorless oil. To this was added 0.65 mL [ 2 H] 3 -iodomethane (11 mmol), immediately yielding a colorless precipitate. The flask was stoppered and allowed to stand in the dark at room temperature for 48 h, and then the precipitate was collected, washed with cold ether, and recrystallized from 5 mL absolute ethanol to yield 108 mg [ 2 H] 3 -NMS iodide (20%) as colorless crystals. The product was analyzed by reverse-phase chromatography with MS, diode-array UV, and evaporative light-scattering detection and demonstrated to be of > 98% chemical purity and > 99% isotopic purity. MS (ESI-TOF), expected for [ 2 H] 3 -C 18 H 21 NO 4 + 321.1891, found 321.1823. Other compounds used in this study were prepared by the NeoGenesis Medicinal Chemistry Group and demonstrated to be > 95% pure by reverse-phase chromatography with MS, diode-array UV, and evaporative light-scattering detection.
Synthesis of [
2
H] 3 -N-methylscopolamine iodide and other compounds
[ 2 H] 3 -N-methylscopolamine iodide ([ 2 H]
Analysis of the influence of allosteric compounds on the dissociation rate of N-methylscopolamine from pM 2 by AS-MS
For each dissociation experiment, NMS was preloaded onto purified pM 2 for 60 min at 25°C in a 40-µL binding reaction consisting of 8 µM pM 2 and 6 µM NMS in TBS-A (50 mM TRIS-Cl [pH 7.5], 150 mM NaCl, and 0.05% digitonin) containing 2.5% DMSO. This was mixed 1:1 with 200 µM allosteric compound (NGD-3366 or W-84 dibromide) predissolved in TBS-A (2.5% DMSO), and the reaction was incubated for 90 min at 25°C. This was then mixed 1:1 with TBS-A containing 400 µM [ 2 H] 3 -NMS and 2.5% DMSO such that the final experimental sample contained 2 µM active pM 2 , 1.5 µM NMS, 50 µM allosteric compound, 200 µM [ 2 H] 3 -NMS, and 2.5% DMSO, and this was immediately chilled to 4°C, and 2-µL aliquots were sampled every 7 min for AS-MS analysis. k q is the association rate constant of the quencher [ 2 H] 3 -NMS and is dependent on the dissociation of the preloaded NMS (k off ).
Radioligand-based binding and dissociation assays
The K d of [ 3 H]-NMS for purified pM 2 was determined by incubating 1.5 × 10 -3 µM active pM 2 in 100 µL of binding buffer (50 mM HEPES, pH 7.5, 100 mM NaCl) with a range of [ 3 H]-NMS (81 Ci/mmol) up to 125 nM. Nonspecific binding was determined by inclusion of 2 µM atropine, and the residual radioactivity present in the 2 µM atropine sample was subtracted from the total signal to obtain the specific binding values. After mixing for 30 min at 25°C, protein was passed through a 1-mL Sephadex G-50 column to remove free unbound radioligand, and bound [ 3 H]-NMS was measured by liquid scintillation counting on a Wallac 1450. K d and nonspecific binding was calculated using the GraphPad Prism equation "saturation binding with ligand depletion," setting the VOL constant to 0.1 mL and SPEACT constant to 6.35 cpm/fmol. Human M 2 AChR (hM 2 )-containing membranes were prepared from the recombinant Chinese hamster ovary (CHO)-K1 cell line, NGTZ-30, that was engineered to express human M 2 AChR (10-20 pmol/mg membrane) with a FLAG-M1 epitope tag at the N-terminus and a 6-histidine tag at the C-terminus. The binding properties of the modified hM 2 AChR expressed on NGTZ-30 were not substantially altered from the native receptor, as determined by affinity rank ordering of various M 2 antagonists in com-petition against [ 3 H]-NMS and as determined by the ability of the cell line to respond normally to M 2 agonists using standard cAMP assays. For competition binding assays, membrane receptor was adjusted to 40 × 10 -6 µM in binding buffer and incubated with 0.3 nM [ 3 H]-NMS and compounds at varying concentrations for 3 h at 25°C, collected onto GF/B filter plates, and washed 8 times with ice-cold TBS-B, and bound [ 3 H]-NMS was measured by scintillation counting on a Wallac 1450. Dissociation rate experiments were performed by premixing hM 2 membranes (40 pM) with 0.3 nM [ 3 H]-NMS for 60 min at 25°C, incubating with allosteric ligands for 10 min at 25°C, chasing with 2 µM atropine for set times until reactions were stopped by rapid filtration and washing over Millipore GF/B filter plates under vacuum filtration, and measuring bound [ 3 H]-NMS by scintillation counting on a Wallac 1450. Analyses and curve fittings of biochemical data were performed using GraphPad Prism software.
Cell-based cAMP assay
Changes in cAMP levels in the hM 2 -expressing cell line NGTZ-30 were measured using a homogeneous time-resolved fluorescence assay (HTRF) following the manufacturer recommendations (CIS-US Incorporated, Bedford, MA). Briefly, cells were seeded at 10,000 cells/well in a flat-bottom 96-well culture plate in 1:1 F12/Dulbecco's modified Eagle's medium (DMEM) containing 3.1 g/L glucose, 2.5 mM L-glutamine, 55 mg/L sodium pyruvate, and 10% Fetaclone II (Hyclone, Logan, UT) and were equilibrated by overnight culture at 37°C and 5% CO 2 . Preincubation with 1 mM IBMX for 60 min was performed before addition of test compounds or carrier (0.2% DMSO), in combination with 30 nM oxotremorine-M and 2 µM forskolin, for a stimulation period of 30 min before lysis and HTRF analysis. Normalized ratiometric values were determined following the manufacturer's recommendations using the following equation: ∆F% = [(SR -SR neg )/SR neg ] × 100, where SR = (A665 nm/A620 nm) and SR neg = sample ratio (SR) of the negative control without fluorescent cAMP conjugate. Data are expressed as percent inhibition of oxotremorine-M-induced down-regulation of forskolinstimulated increases in intracellular cAMP of cell line NGTZ-30.
Guinea pig atrial assay
Compounds were tested by MDS Pharma Services (Bothell, WA) in a guinea pig atrial assay measuring inhibition of methacholine-induced negative inotropy. 19 Atria excised from Duncan Hartley guinea pigs were placed in 10-mL baths of McEwen's buffer, pH 7.4, at 34°C, and after equilibration and addition of compounds, inhibition of the methacholine-induced inotropic response was measured over an assessment period of 5 min. Data were normalized to vehicle (0.1% DMSO), and greater than 50% inhibition was considered significant in this assay system.
RESULTS
Characterization of purified pM 2 AChR by traditional and AS-MS binding assays
We chose the muscarinic M 2 AChR for the proof-of-concept screening because it is relatively well characterized and amenable to purification and a variety of agonists, and antagonists were commercially available for binding studies. At the initiation of this study, a suitable human cDNA clone was not available; therefore, we used a porcine cDNA to develop an expression system. The porcine M 2 AChR (pM 2 ) is highly homologous to human M 2 (hM 2 ) with 97.4% identity and has nearly identical binding affinities for muscarinic ligands. 20 A honeybee melittin signal sequence and FLAG M1 epitope tag was engineered at the N-terminus of the open reading frame of pM 2 to enhance proper membrane targeting and folding of the receptor. 21 Consistent with a previous report that the active M 2 receptor can be expressed in the baculovirus expression system, 22 we produced Sf9 cell membranes yielding > 10 pmol of pM 2 per milligram of membrane protein. The melittin signal sequence was efficiently cleaved to reveal the FLAG-M1 epitope that was subsequently used for affinity purification of digitonin-solubilized receptor by anti-FLAG M1-agarose and fluid phase liquid chromatography. A final receptor purity of approximately 70% to 80% and concentration of > 20 µM was routinely obtained (Fig. 1A) . The monomeric form of the receptor ([pM 2 ] 1 ) had the expected molecular weight of approximately 51.6 kDa. 23 Purified integral membrane proteins in detergent micelles may become unfolded and structurally denatured during screening. To determine if receptor stability would be maintained during the critical AS and SEC steps of the screening process, we first performed control binding experiments by premixing purified pM 2 with randomly selected combinatorial libraries (2500 compounds each at 1 µM) into which known M 2 antagonists were spiked. Concentrations of each known ligand were chosen to provide adequate MS signal response, the magnitude of which is dependent on affinity as well as MS sensitivity of each compound. The MS signal of atropine, QNB, AFDX-116, or pirenzepine was equivalent when combined with pM 2 alone or spiked into libraries, indicating that the receptor is fully functional throughout the screening process (Fig.  1B) . The finding that agonists McN-A343 and ABuTs are also detected by the same experimental method (Fig. 1C) further supports this conclusion. Depending on the control antagonist and agonist or specific library used in these preliminary assays, slight augmentation or attenuation of the MS response signals was observed, which may result from library-specific stabilization or perturbation effects on the GPCR-ligand complex at the AS, SEC, or RPC-MS (ion suppression) stage of the assay process. The observed binding is specific because the same agonists were not detected when premixed with another integral membrane protein, COX-1 (Fig. 1C) .
We further characterized the purified pM 2 by performing a radioligand binding assay using Sephadex G-50 gel filtration to separate unbound from bound [ 3 H]-NMS. Saturation binding re- Fig. 2A) , a value 10-to 20-fold higher than expected for intact pM 2 in membrane. This shift in K d is likely due to slight alterations in receptor structure, as has been reported for other solubilized GPCRs present in detergent micelles. [24] [25] [26] [27] [28] It has been previously shown that AS-MS can be used to characterize ligand-receptor binding affinities. 16 Therefore, we performed a saturation binding experiment using 1 µM of pM 2 and NMS concentrations ranging from 0 to 4 µM using AS-MS to measure bound NMS. As shown in Figure 2B , NMS binding to pM 2 was saturable, and the binding affinity was similar to that obtained by the Sephadex G-50-based method (K d = 6.2 ± 4 nM), further suggesting that pM 2 activity remains unchanged during the AS-MS process.
The structural integrity of a purified soluble protein can also be inferred from competitive binding experiments between differing ligands. The AS-MS-based ACE 50 method allows one to distinguish whether ligands are directly competitive for a single binding site or bind to differing sites on a receptor. 16 Using the ACE 50 method, we tested whether increasing concentrations of orthosteric-binding NMS premixed with pM 2 would compete off binding of the orthosteric M 2 /M 4 antagonist AF-DX-384. 27 As shown in Figure 2C , binding of AF-DX-384 was competed off by increasing concentrations of NMS, and a plot of the MS response ratio (signal from NMS divided by signal from AF-DX-384) versus the NMS concentration revealed a distribution with a linear fit, signifying that these ligands were directly competing for the same binding site on pM 2 , consistent with their known binding properties, as shown by conventional radioligand binding assays. 16, 29 From these various binding experiments, we concluded that the purified pM 2 preparation retained sufficient stability and binding activity during the AS-MS assay to be used for a screening campaign using AS-MS to discover new M 2 ligands from smallmolecule combinatorial libraries.
Discovery of novel pM 2 AChR ligands by screening small-molecule combinatorial libraries using AS-MS
We conducted a screen of 244 library pools (356,474 compounds total) consuming 5 nmol (250 µg) of the purified pM 2 AChR. A total of 48 primary ligands were identified and confirmed as pM 2 -specific ligands in rapid follow-up AS-MS binding experiments. The compounds were then synthesized in multimilligram scale, purified, and used in additional biochemical and AS-MS-based assays to characterize binding. Of the 48 ligands, 24 were validated as biochemically active hits based on competitive displacement of [ 3 H]-NMS from insect membrane preparations expressing pM 2 (data not shown). Ligands were prioritized based on ACE 50 binding analyses using AS-MS to identify those compounds that were most resistant to displacement from purified pM 2 by increasing concentrations of the competitive antagonist atropine. The results of this ACE 50 experiment were previously reported. 16 Three compounds-NGD-3346, NGD-3348, and NGD-3350-were chosen for further study (Fig. 3A) . These ligands are structural congeners, and of all the compounds tested, NGD-3350 shows the highest binding affinity to pM 2 . 16 The AS-MS-based binding experiments revealed that all the ligands show saturable single-site binding to pM 2 like the M 2 -specific control antagonist AF-DX-116 29, 30 (Fig. 3B) . were obtained for AF-DX-116, NGD-3346, NGD-3348, and NGD-3350, respectively. Indirect affinity constants (K i ) of AF-DX-116, NGD-3346, 3348, and 3350 were also determined by measuring competitive displacement of [ 3 H]-NMS from the human receptor (hM 2 ) expressed on CHO-K1 cell membranes (cell line NGTZ-30). The resultant K i constants correspond well with the K d values derived from the AS-MS assays (Fig. 3C) . NGD-3350 is therefore the tightest binding M 2 ligand (K i = 0.2 µM) discovered from this proof-of-concept screen, consistent with our previous observation. 16 
NGD-3350 is an M 2 -selective AChR orthosteric antagonist
The ability of NGD-3350 to inhibit the binding of [ 3 H]-NMS to hM 2 expressed in membrane preparations (Fig. 3C) suggested that it might be directly competitive with compounds binding to the orthosteric antagonist binding site of the M 2 AChR. To test this hypothesis, we performed AS-MS-based ACE 50 assays to study the mode of binding of NGD-3350. Figure 4A shows that NMS inhibits binding of NGD-3350 to purified pM 2 , and NGD-3350 inhibits binding of AF-DX-116 ( Fig. 4B) , as well as AF-DX-384 and the classic muscarinic antagonist QNB (Fig. 4C) . The linear plots of titrant/competitor response ratios and titrant concentrations shown in Figure 4D -F indicate direct competition. The data confirm that NGD-3350 is directly competitive with orthosteric antagonists of pM 2 (Fig. 4D-F) .
The receptor-binding selectivity of NGD-3350 was also examined. Like the antagonists atropine and AF-DX-116, at 25-µM concentrations, NGD-3346, NGD-3348, and NGD-3350 all displace 1 nM [ 3 H]-NMS from binding to membrane preparations that contain the hM 2 AChR but do not displace 1 nM [ 3 H]-CGP12177 from binding to membrane preparations that contain the human β2-adrenergic receptor (Fig. 5A) . When assayed for the ability to displace [ 3 H]-NMS from the other muscarinic AChR subtypes, NGD-3350 shows a 38-, > 100-, 34-, and 27-fold selectivity for M 2 over the M 1 , M 3 , M 4 , and M 5 subtypes, respectively (Fig. 5B) . The selectivity of NGD-3350 for M 2 versus M 1 and M 4 subtypes is approximately 5-fold greater than that of AF-DX-116 ( Fig. 5C) .
NGD-3350 is a functional antagonist of the muscarinic M 2 AChR
Agonism of the M 2 AChR induces association with Gα i/o proteins that directly inhibit cellular adenylyl cyclase activity. 31 Using the NGTZ-30 cell line, we tested NGD-3346, NGD-3348, and NGD-3350 all show antagonist activity, with IC 50 values of 0.22, 3.2, 4.5, and 0.34 µM, respectively (Fig. 6A) . As another measure of functional antagonism by NGD-3350, the compounds were tested in the classic guinea pig left atrial assay measuring antagonism of methacholine-induced negative inotropy, which is stimulated through the M 2 AChR. 19, 32 Only NGD-3350 shows significant (> 50%) antagonism at 30 µM (Fig. 6B) , and a dose-response experiment suggests an IC 50 value of approximately 7 µM (Fig.  6C) .
NGD-3366 binds to the muscarinic M 2 AChR outside of the orthosteric binding pocket
During follow-up ACE 50 experiments to characterize additional ligands identified in our screen, we discovered that NGD-3366 ( Fig. 7A) binds to pM 2 , and its binding is not prevented by saturating concentrations of the orthosteric antagonists NMS or NGD-3350 ( Fig. 7B,C) . Plots of the titrant/competitor response ratios versus increasing titrant concentrations suggest that ternary complexes are formed between pM 2 , NGD-3366, and NMS or pM 2 , NGD-3366, and NGD-3350 ( Fig. 7E,F) . In a reciprocal biochemical assay, we found that at high concentrations, NGD-3366 is able to displace binding of [ 3 H]-NMS to hM 2 expressed on NGTZ-30 membranes (K i = 45 µM; Fig. 7D) . These observations suggest that NGD-3366 might be a weak allosteric antagonist that binds outside of the orthosteric binding pocket of M 2 that is occupied by NMS.
The allosteric antagonist compound W-84 binds to a common allosteric site on the M 2 AChR that resides above the orthosteric binding pocket. 4 Because of this binding mode, W-84 may form a "cap" on the receptor, impeding the dissociation of compounds that are bound in the orthosteric pocket and effectively decreasing their dissociation rate. 33, 34 Therefore, we tested whether NGD-3366 could bind in a manner analogous to W-84 and alter the dissociation rate of the orthosteric ligand NMS from the M 2 AChR. As shown in Figure 8A , both NGD-3366 and W-84 decrease the dissociation rate of [ 3 H]-NMS from hM 2 AChR expressed on NGTZ-30 membranes (Fig. 8A) .
As an additional test of this binding mode, we performed a similar dissociation experiment using AS-MS. Purified pM 2 was preloaded with NMS, incubated with W-84 or NGD-3366, and then the dissociation of NMS was assayed over time by chasing with an excess of the isotopically labeled competitor ligand [ 2 H] 3 Figure 8B , the AS-MS dissociation rate experiment revealed that both NGD-3366 and W-84 decrease the dissociation rate of NMS from pM 2 . The corresponding changes in the rate of [ 2 H] 3 -NMS association effected by both W-84 and NGD-3366 also support this conclusion, and the convergence of signals for [ 2 H] 3 -NMS at the last 100-min time point indicates that neither W-84 nor NGD-3366 act by irreversibly denaturing the receptor. The dissociation rates measured by AS-MS are 4fold faster than those determined by radioligand-based biochemical assay (Fig. 8B) , suggesting that this method does not perfectly mimic standard biochemical methods using radioligands. This difference may be associated with limitations in AS-MS sampling speed. There is a time lag of approximately 2 min between sample retrieval by the HPLC autosampler and the final liquid chromatography/mass spectrometry (LC/MS) ligand detection step, and samples could only be acquired at 7-min intervals. Therefore, k off rates under 5 min are based purely on curve fitting and are therefore inherently less accurate. Nevertheless, the relative changes in the dissociation rates observed by AS-MS are informative and consistent with the results from radioligand-based assays, suggesting that NGD-3366 has a binding mode similar to W-84.
DISCUSSION
In this report, we have demonstrated the use of AS-MS for early stage hit discovery and ligand characterization at many levels. First, we have shown that AS-MS-based ligand-binding assays can be used to validate the structural integrity of the orthosteric site of a purified GPCR prior to its use in subsequent screening campaigns. Purified preparations of digitonin-solubilized pM 2 were validated for screening by 3 types of AS-MS experiments: we demonstrated specific binding of pM 2 to known muscarinic M 2 AChR agonists and antagonists spiked into random combinatorial libraries, we demonstrated that the AS-MS-based K d of NMS binding to pM 2 was similar to that determined by traditional assays using [ 3 H]-NMS and Sephadex G-50 gel filtration, and we demonstrated that NMS behaved classically as an orthosteric competitor of AF-DX-384 in the ACE 50 assay. AS-MS-based assays (K d , k off , and ACE 50 ) may provide an alternative to, or complement, existing traditional biochemical assay methodologies when one needs to validate that a purified receptor has expected ligand-binding activity.
Second, we have shown that AS-MS can be used as a discovery platform for identifying multiple classes of GPCR ligands in a single screening campaign. In our proof-of-concept screen of M 2 AChR against 244 library pools (356,474 compounds total), we consumed under 5 nmol (250 µg) of purified receptor and identified 48 primary hits that showed confirmed binding in follow-up AS-MS-based binding experiments. Of these, 50% showed activity in radioligand competition binding assays using pM 2 -expressing membranes. Several biologically active antagonists were identified, and one in particular, NGD-3350, displayed submicromolar affinity and a greater degree of selectivity for the M 2 AChR subtype than the classic M 2 -specific antagonist AF-DX-116. NGD-3350 was shown to be a bioactive M 2 antagonist in preliminary cell-based experiments measuring antagonism of oxotremorineinduced attenuation of forskolin-stimulated intracellular cAMP, as well as in an organ-based experiment using a standard ex vivo guinea pig atrial assay of M 2 function. NGD-3350 may be a useful molecular probe for future studies of muscarinic M 2 AChR pharmacology. Finally, we have shown that AS-MS-based assays can be used to characterize receptor binding properties of newly discovered ligands. The relative binding affinities and binding modes (orthosteric vs. allosteric) of initial pM 2 hits were characterized by ACE 50 assays using the antagonist NMS as a reference titrant. This led to the early identification of NGD-3350 as an interesting and relatively high-affinity orthosteric M 2 hit. NGD-3350 was further characterized by measuring its K d with AS-MS, by applying standard biochemical radioligand displacement assays using M 2 -expressing membranes, and by performing additional ACE 50 assays using other well-defined M 2 antagonists (QNB, AF-DX-116, and AF-DX-384). In follow-up studies of M 2 ligands that could not be classified as orthosteric binders, we discovered that NGD-3366 binding to pM 2 could not be displaced by the orthosteric ligand NMS in ACE 50 experiments, indicating that a ternary complex is formed between pM 2 , NMS, and NGD-3366. In an equilibrium binding reaction using membrane hM 2 , NGD-3366 is a weak competitor of in a mode similar to the allosteric antagonist W-84. 33, 34 Unfortunately, W-84 is not directly detectable in AS-MS due to its physicochemical properties, and therefore we were not able to perform an ACE 50 experiment to directly measure the competition of W-84 versus NGD-3366 and determine orthosteric or allosteric binding for these 2 ligands. However, to confirm the proposed allosteric binding mode of NGD-3366, we performed dissociation rate studies using both biochemical and AS-MS-based methods, demonstrating that NGD-3366 retards the dissociation of [ 3 H]-NMS from the M 2 AChR in a manner similar to the known allosteric ligand W-84 and confirming that NGD-3366 is a specific ligand to M 2 AChR. Although we have shown that AS-MS-based screening of combinatorial libraries can be a potentially useful method for discovering new ligands of integral membrane proteins, we should highlight the limitations of this methodology. First, this technology platform requires a purified (> 70% purity) soluble active receptor preparation (> 0.5 µM active). Only those receptors that can maintain an active structure throughout the detergent solubilization, affinity purification, and concentration or dialysis steps in the formulation process will be suitable for AS-MSbased applications. Second, there is the liability associated with the fact that a detergent-solubilized GPCR may never reflect the true physiological structure of a GPCR embedded in membrane, as might be expected in most membrane-and cell-based assays. As advances in integral membrane protein expression, purification, and biophysical and structural studies progress, so will the opportunities for applying AS-MS-based assays for receptor screening and characterization. Future targets for AS-MS might be receptors beyond the GPCR family, for example, ion channels, transporters, integrins, and cytokine receptors. Third, we should emphasize that all AS-MS-based assays are dependent on the availability of ligands having suitable physicochemical properties for detection by MS. Experimental ligands of interest may not always have suitable properties. Typically, they must appropriately ionize and be routinely detectable at levels down to 100 to 200 fmoles. Highly hydrophobic compounds lacking suitable charged groups are often not amenable to detection in the AS-MS platform used in this report. Indeed, some of the compounds discovered in our primary AS-MS-based screen of M 2 AChR displayed relatively weak signals in the mass spectrometer that were sufficient for initial hit identification but too weak for follow-up K d and ACE 50 assays. Obviously, to ensure that weak hits in primary screens are not mistaken as false negatives, they should be tested in alternative assays not reliant on MS for detection. The usefulness of compounds for AS-MS-based assays can be easily verified ahead of time by stan- dard LC/MS analyses. Finally, we should emphasize that the combinatorial small-molecule libraries used in this study were specially designed for use in the AS-MS screening platform. 16, 17 As is the case for any high-throughput drug screening platform, the discovery outcome can be biased by the assay methodology used. For AS-MS-based screening, although using affinity selection may reduce bias because it allows discovery of all classes of ligands (orthosteric and allosteric), bias is nevertheless introduced at another level because all screening libraries to be used for AS-MS must contain ligands detectable by MS. Reducing bias while increasing the chances of finding drug-like hits presents a unique synthesis challenge to those designing and implementing smallmolecule combinatorial libraries for an AS-MS screening platform. Future advancements in chemical library development for AS-MS platforms may greatly improve upon the current discovery potential of this discovery technology.
